



Ferro Pfanstiehl Laboratories, Inc.
1219 Glen Rock Ave.
Waukegan, IL 60085
Tel: (847) 623-0370
Toll Free: (800) 383-0126
Fax: (847) 623-9173
Web: www.ferro.com (Key: Pharmaceuticals)
E-mail: custserv@ferro.com

Vital Statistics

Year Founded: 1919

Number of Employees: 90+

Key Personnel: Michelle Fromholzer, Business Director; Ed Mar, Ph.D., Director of Chemical & Process Technology; Pratibhash Chattopadhyay, Ph.D., Director of New Technology; Roger Voight, Director, Quality; Martin Meyer, Manufacturing Director

Who We Are

FERRO PFANSTIEHL LABORATORIES, INC. is a wholly-owned subsidiary of Ferro Corporation (NYSE:FOE), a leading global producer of technology-based performance materials for manufacturers. Headquartered in Cleveland, Ohio, Ferro has operations in more than 20 countries, sells its products in more than 100 countries and reported sales of \$2.2 billion in 2007. Ferro Pfanstiehl Laboratories, Inc., based in Waukegan, Illinois, provides fee-for-service development and commercial manufacturing of active pharmaceutical ingredients (APIs). The Company's emphasis is on small-molecule new chemical entities (NCEs), and it also offers expertise and containment facilities for high potency and cytotoxic HPAPIs. Ferro Pfanstiehl has more than 20 active U.S. and international Drug Master Files.

Major Markets

FERRO PFANSTIEHL WORKS CLOSELY with clients ranging from virtual pharmaceutical companies to the world's largest multinational pharmaceutical and biopharmaceutical producers as a solution or product provider. Its facilities and expertise are ideally suited for the cGMP development and manufacturing of APIs and improved drug delivery platform solutions. Ferro Pfanstiehl meets all international regulatory and multi-compendial standards.

Services Offered

A TRUSTED PARTNER FROM DEVELOPMENT through commercialization, Ferro Pfanstiehl specializes in contract API development from preclinical through commercial quantities under ICH Q7A guidelines. With more than 40 years of cGMP experience,

the Company is uniquely qualified to move NCEs from the laboratory to the commercial marketplace.

Contract services include:

- Custom synthesis of APIs and advanced intermediates
- Process development & cGMP scale-up
- Process, method & cleaning validation
- Impurity profiling, stability protocol development and testing
- Analytical test method development and validation
- Clinical Trial Material (CTM) and supporting documentation
- Drug Master File (DMF) development and maintenance

Facilities

HPAPIs & other small-molecule NCEs

- Validated Class IV Kilo Lab full containment facility with hydrogenation capabilities producing < 1 kg to 5 kg in 100L scale GL and Hastalloy reactors at -70–200° C
- Development and commercial scale multi-purpose containment manufacturing facility with 1,200 gallons of primary reactor capacity and Class 100,000 recovery areas for isolation, drying & milling
- Full 21 CFR Part 11 compliant Analytical Services Laboratory



Kilo Lab Facility

www.ferro.com